Cyanotech (Cyanotech) ROCE % : -17.79% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Cyanotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cyanotech's annualized ROCE % for the quarter that ended in Dec. 2023 was -17.79%.

Cyanotech ROCE % Historical Data

The historical data trend for Cyanotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyanotech ROCE % Chart

Cyanotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-13.58

4.62

5.83

9.84

-11.96

Cyanotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-6.35	-21.47	-23.13	-12.76	-17.79

Cyanotech ROCE % Calculation

Cyanotech's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-2.92	/	( ( (32.045 - 4.821)	+	(29.728 - 8.103) )	/ 2 )
	=	-2.92	/	( (27.224	+	21.625)	/ 2 )
	=	-2.92	/	24.4245
	=	-11.96 %

Cyanotech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-3.392	/	( ( (28.082 - 8.659)	+	(27.254 - 8.538) )	/ 2 )
	=	-3.392	/	( ( 19.423	+	18.716 )	/ 2 )
	=	-3.392	/	19.0695
	=	-17.79 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cyanotech (OTCPK:CYAN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cyanotech ROCE % Related Terms

Thank you for viewing the detailed overview of Cyanotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyanotech (Cyanotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Cyanotech Corp (OTCPK:CYAN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

73-4460 Queen Kaahumanu Highway, Suite 102, Kailua-Kona, HI, USA, 96740

Website

https://www.cyanotech.com

Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The company's products include BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. BioAstin Hawaiian Astaxanthin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health. It derives maximum revenue from the Packaged product and geographically from the United States.

Executives

Kakuk Collette Nicole	officer: Chief Strategic Comml Officer	73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Michael A / Davis	director, 10 percent owner	1621 JUANITA LANE, TIBURON CA 94920
Angela May Mcelwee	director	73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Charles Jason Hartmann	officer: VP, Sales & Marketing	73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Glenn Jensen	officer: VP-Operations	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA-KONA HI 96740
Jennifer M. Johansen	officer: VP of Quality	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA HI 96740
Walter Bennett Menzel	director	45 MOUNT TIBURON ROAD, TIBURON CA 94920
Felicia I Ladin	officer: CFO, VP Fin & Admin, Treasurer	26 CORPORATE CIRCLE, ALBANY NY 12203
Matthew Keith Custer	officer: Vice President, Gen Mgr	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA HI 96740
Amy Beth Nordin	officer: VP, HR, Secretary	73-4460 QUEEN KAAHUMANU HWY. SUITE 102, KAILUA-KONA HI 96740
Brian Brett Orlopp	officer: CFO, VP, Treasurer, Secretary	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA CA 96740
Gerald J Watts	officer: COO	2530 RED HILL AVE, SANTA ANA CA 92705
Mawae Morton	officer: President	7473 MAKA'A STREET, HONOLULU HI 96825
Nancy E Katz	director	CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
David M Mulder	director	21771 CALATRAVA, MISSION VIEJO CA 92692